Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
Background. Immune checkpoint inhibitors (ICIs) have been evaluated as neoadjuvant treatment in urothelial carcinoma (UC) patients, with these agents reporting encouraging pathologic complete response (pCR) rates. Herein, we performed a systematic review and meta-analysis aimed at evaluating the inc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/4/1038 |
| _version_ | 1797479142356156416 |
|---|---|
| author | Alessandro Rizzo Veronica Mollica Matteo Santoni Gennaro Palmiotti Francesco Massari |
| author_facet | Alessandro Rizzo Veronica Mollica Matteo Santoni Gennaro Palmiotti Francesco Massari |
| author_sort | Alessandro Rizzo |
| collection | DOAJ |
| description | Background. Immune checkpoint inhibitors (ICIs) have been evaluated as neoadjuvant treatment in urothelial carcinoma (UC) patients, with these agents reporting encouraging pathologic complete response (pCR) rates. Herein, we performed a systematic review and meta-analysis aimed at evaluating the incidence of pCR in UC patients treated with neoadjuvant ICI. Moreover, we investigated the impact of PD-L1 expression in this patient population, exploring the possible role of PD-L1 status as predictive biomarker. Materials and Methods. We retrieved all the relevant trials through PubMed/Medline, Cochrane Library and EMBASE; moreover, proceedings of the main international oncological meetings were also searched for relevant abstracts. Eligible trials assessed pre-operative ICI in UC patients. Results. Our meta-analysis has highlighted a pooled pCR rate of 36.6% in the overall population; interestingly, pCR was higher in PD-L1 positive compared with PD-L1 negative UCs (49.5% versus 35.1%, respectively). Conclusions. Positive signals emanating from neoadjuvant immunotherapy should encourage the scientific community to persist in the long road toward finding more effective treatments for UC patients. |
| first_indexed | 2024-03-09T21:41:21Z |
| format | Article |
| id | doaj.art-d1ba71c648244d64ac93ee88f0178b73 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:41:21Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-d1ba71c648244d64ac93ee88f0178b732023-11-23T20:30:43ZengMDPI AGJournal of Clinical Medicine2077-03832022-02-01114103810.3390/jcm11041038Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-AnalysisAlessandro Rizzo0Veronica Mollica1Matteo Santoni2Gennaro Palmiotti3Francesco Massari4Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni—15, 40138 Bologna, ItalyMedical Oncology Unit, Macerata General Hospital, 62100 Macerata, ItalyStruttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni—15, 40138 Bologna, ItalyBackground. Immune checkpoint inhibitors (ICIs) have been evaluated as neoadjuvant treatment in urothelial carcinoma (UC) patients, with these agents reporting encouraging pathologic complete response (pCR) rates. Herein, we performed a systematic review and meta-analysis aimed at evaluating the incidence of pCR in UC patients treated with neoadjuvant ICI. Moreover, we investigated the impact of PD-L1 expression in this patient population, exploring the possible role of PD-L1 status as predictive biomarker. Materials and Methods. We retrieved all the relevant trials through PubMed/Medline, Cochrane Library and EMBASE; moreover, proceedings of the main international oncological meetings were also searched for relevant abstracts. Eligible trials assessed pre-operative ICI in UC patients. Results. Our meta-analysis has highlighted a pooled pCR rate of 36.6% in the overall population; interestingly, pCR was higher in PD-L1 positive compared with PD-L1 negative UCs (49.5% versus 35.1%, respectively). Conclusions. Positive signals emanating from neoadjuvant immunotherapy should encourage the scientific community to persist in the long road toward finding more effective treatments for UC patients.https://www.mdpi.com/2077-0383/11/4/1038immunotherapyimmune checkpoint inhibitorspembrolizumabatezolizumaburothelial carcinomaneoadjuvant |
| spellingShingle | Alessandro Rizzo Veronica Mollica Matteo Santoni Gennaro Palmiotti Francesco Massari Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis Journal of Clinical Medicine immunotherapy immune checkpoint inhibitors pembrolizumab atezolizumab urothelial carcinoma neoadjuvant |
| title | Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis |
| title_full | Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis |
| title_fullStr | Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis |
| title_full_unstemmed | Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis |
| title_short | Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis |
| title_sort | pathologic complete response in urothelial carcinoma patients receiving neoadjuvant immune checkpoint inhibitors a meta analysis |
| topic | immunotherapy immune checkpoint inhibitors pembrolizumab atezolizumab urothelial carcinoma neoadjuvant |
| url | https://www.mdpi.com/2077-0383/11/4/1038 |
| work_keys_str_mv | AT alessandrorizzo pathologiccompleteresponseinurothelialcarcinomapatientsreceivingneoadjuvantimmunecheckpointinhibitorsametaanalysis AT veronicamollica pathologiccompleteresponseinurothelialcarcinomapatientsreceivingneoadjuvantimmunecheckpointinhibitorsametaanalysis AT matteosantoni pathologiccompleteresponseinurothelialcarcinomapatientsreceivingneoadjuvantimmunecheckpointinhibitorsametaanalysis AT gennaropalmiotti pathologiccompleteresponseinurothelialcarcinomapatientsreceivingneoadjuvantimmunecheckpointinhibitorsametaanalysis AT francescomassari pathologiccompleteresponseinurothelialcarcinomapatientsreceivingneoadjuvantimmunecheckpointinhibitorsametaanalysis |